NCT05508932 Atrial Fibrillation in Beta-Thalassemia
| NCT ID | NCT05508932 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital of Ferrara |
| Condition | Atrial Fibrillation |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2022-09-01 |
| Primary Completion | 2032-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2022-09-01 with a primary completion date of 2032-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to evaluate the clinical, laboratory and instrumental differences that exist between beta-thalassemia patients with atrial fibrillation and those not affected by arrhythmia.
Eligibility Criteria
Inclusion Criteria: 1. Transfusion-dependent Beta-thalassemia; 2. Follow-Up at the Cardiology Unit of the University Hospital of Ferrara; 3. Electrocardiogram performed; 4. Echocardiogram performed. Exclusion Criteria: 1. Age \<18 years; 2. State Of pregnancy; 3. Inability to give informed consent.
Frequently Asked Questions
Who can join the NCT05508932 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05508932 currently recruiting?
Yes, NCT05508932 is actively recruiting participants. Visit ClinicalTrials.gov or contact University Hospital of Ferrara to inquire about joining.
Where is the NCT05508932 trial being conducted?
This trial is being conducted at Ferrara, Italy.
Who is sponsoring the NCT05508932 clinical trial?
NCT05508932 is sponsored by University Hospital of Ferrara. The trial plans to enroll 350 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.